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The DNA damage checkpoint response delays cell cycle progression
upon DNA damage and prevents genomic instability. Genetic
analysis has identified sensor, mediator, signal transducer, and
effector components of this global signal transduction pathway.
Here we describe an in vitro system with purified human check-
point proteins that recapitulates key elements of the DNA damage
checkpoint. We show that the damage sensor ATR in the presence
of topoisomerase II binding protein 1 (TopBP1) mediator/adaptor
protein phosphorylates the Chk1 signal-transducing kinase in a
reaction that is strongly dependent on the presence of DNA
containing bulky base lesions. The dependence on damaged DNA
requires DNA binding by TopBP1, and, indeed, TopBP1 shows
preferential binding to damaged DNA. This in vitro system provides
a useful platform for mechanistic studies of the human DNA
damage checkpoint response.
Chk1 kinase  damage recognition  signal transduction 
topoisomerase II binding protein 1
Most of our knowledge about the DNA damage checkpointresponse is based on genetic data from model organisms,
including budding and fission yeasts and humans and the Xeno-
pus egg extract system. These studies have identified damage
sensors, mediators, signal transducers, and effectors as key
components of this signal-transduction pathway (1–3). The
phosphatidylinositol 3-kinase-related protein kinase (PIKK)
family members have been shown to be key DNA damage
sensors and signal transducers in the checkpoint response. Of
these, ATM is mainly responsible for initiation of the checkpoint
response elicited by double-strand breaks caused by ionizing
radiation or radiomimetic agents. Some semidefined systems for
the ATM-mediated checkpoint response have been described
recently (4–8). Another PIKK family member, ATR, initiates
the DNA damage checkpoint response caused by UV radiation
and UV-mimetic agents that produce base damage such as
N-acetoxy-2-acetylaminofluorene (N-Aco-AAF). Although this
important signal-transduction pathway has been characterized in
some detail by using Xenopus egg extracts (9–15) and in human
cell-free systems (16, 17), only recently have partial in vitro
systems been developed with a subset of either Xenopus (14, 15)
or yeast (18) checkpoint proteins. Currently, there is no well
defined system for ATR-mediated DNA damage checkpoint
response in humans. Recently, it has been shown that the
multifunctional XtopBP1 protein, which is known to be required
for the ATR-mediated checkpoint (19), activates the ATR
kinase on downstream targets, in particular the Chk1 signal-
transducing kinase, in the absence of DNA or any other check-
point protein except the ATR-interacting protein (ATRIP) (14).
Here we describe a human in vitro system in which ATR
phosphorylates Chk1 kinase in a reaction that depends on
topoisomerase II binding protein 1 (TopBP1) and is strongly
stimulated by DNA containing bulky DNA adducts. We believe
this is a useful system for the ultimate development of an in vitro
human checkpoint response dependent on all checkpoint pro-
teins identified by genetic methods. Such a system would open
new opportunities for mechanistic studies of the human DNA
damage checkpoint response.
Results
TopBP1-Dependent Stimulation of ATR Kinase Activity by DNA. We
were interested in developing a human ATR-mediated check-
point system in vitro. To this end, we purified human ATR–
ATRIP, TopBP1, and Chk1 proteins. The ATR–ATRIP com-
plex was purified from HeLa cell-free extracts (Fig. 1 A and B)
to a high degree of purity, free of other PIKK kinases that could
possibly complicate the interpretation of the results. TopBP1
and Chk1 were purified from Escherichia coli and baculovirus-
infected insect cells, respectively [supporting information (SI)
Fig. 7]. Fractions containing highly purified ATR–ATRIP were
tested for the ability to phosphorylate Chk1-S345 in the presence
and absence of TopBP1 (Fig. 1C). We found that in reaction
mixtures that were of low ionic strength, ATR phosphorylated
Chk1 in a manner virtually dependent on TopBP1, which is in
agreement with previous reports (14, 20) (Fig. 2, lane 3).
However, when the ionic strength was increased to more phys-
iologically relevant levels, the stimulation of ATR kinase by
TopBP1 was, by and large, eliminated (Fig. 2, lanes 7 and 11). We
reasoned that under these conditions, the checkpoint-signaling
reaction may be reestablished by including DNA in the reaction.
Fig. 2 shows the phosphorylation of Chk1 by ATR in the absence
and presence of DNA with and without TopBP1. Under higher
ionic strength reaction conditions, TopBP1 has no measurable
effect on the kinase activity of ATR (lane 7). Significantly,
however, the addition of DNA to this reaction resulted in a 7-fold
stimulation of ATR activity (lane 8), restoring the Chk1 phos-
phorylation to levels observed in the low ionic strength buffer
(lane 3).
Effects of Various DNA Substrates on TopBP1-Dependent ATR Kinase
Activity. The dramatic TopBP1-dependent stimulation of ATR
kinase activity that we observed in Fig. 2 was achieved with
double-stranded plasmid DNA. We reasoned that a more phys-
iologically relevant form of DNA might result in further stimu-
lation of ATR in our in vitro reactions. As a model for both
primer templates and excision repair gaps, deca-primed DNA
(ten 30-mer primers, roughly equally spaced along the DNA
circle) has been reported to be optimal for stimulating Saccha-
romyces cerevisiae Mec1ATR kinase (18). The addition of deca-
primed DNA to our reactions results in up to a 5-fold stimulation
of Chk1 phosphorylation by ATR in the presence of TopBP1
(Fig. 3, lanes 6–8). However, the stimulatory effect was not
Author contributions: J.-H.C. and L.A.L.-B. contributed equally to this work; J.-H.C., L.A.L.-B.,
and A.S. designed research; J.-H.C. and L.A.L.-B. performed research; J.-H.C. and L.A.L.-B.
contributed new reagents/analytic tools; J.-H.C., L.A.L.-B., and A.S. analyzed data; and J.-H.C.,
L.A.L.-B., and A.S. wrote the paper.
The authors declare no conflict of interest.
Freely available online through the PNAS open access option.
Abbreviations: N-Aco-AAF, N-acetoxy-2-acetylaminofluorene; ATRIP, ATR-interacting pro-
tein; kd, kinase-dead; PIKK, phosphatidylinositol 3-kinase-related protein kinase; RPA,
replication protein A; TopBP1, topoisomerase II binding protein 1.
*To whom correspondence should be addressed. E-mail: azizsancar@med.unc.edu.
This article contains supporting information online at www.pnas.org/cgi/content/full/
0706013104/DC1.
© 2007 by The National Academy of Sciences of the USA








specific to deca-primed DNA, because we observed essentially
the same levels of stimulation of the TopBP1-dependent ATR
kinase activity by both single-stranded (lanes 3–5) and double-
stranded (lanes 9–11) plasmid DNAs. Because a number of
studies have indicated that replication protein A (RPA)-covered
single-stranded DNA is a common, if not universal, signal for
ATR-mediated checkpoint activation (21, 22), we tested the
effect of RPA on the reaction by using both deca-primed and
double-stranded DNA. We observed only a slight stimulation
upon the addition of RPA with both types of DNA (SI Fig. 8).
Although these results do not eliminate RPA-covered single-
stranded DNA or template/primer structures as checkpoint
signals, they do show that under our experimental conditions of
physiological ionic strength and limiting concentrations of
TopBP1, all forms of DNA tested act similarly in activating ATR
in a TopBP1-dependent manner.
TopBP1-Dependent Stimulation of ATR Kinase Activity by DNA Con-
taining Bulky Base Lesions. Next, we tested DNA damaged by
N-Aco-AAF and UV light. Both of these agents produce bulky
base adducts, AAF-guanine and pyrimidine dimers, respectively.
Moreover, evidence has been obtained indicating that check-
point proteins bind directly to these lesions, leading to check-
point activation (23, 24). Hence, we reasoned that DNA dam-
aged by these agents may specifically activate ATR in the
presence of TopBP1. In Fig. 4A, we show the effect of various
concentrations of N-Aco-AAF-damaged DNA on the kinase
activity of ATR. As is apparent from this figure, damaged DNA
stimulates the ATR kinase 20-fold more than the level of
TopBP1 alone, and more importantly, damaged DNA stimulates
the TopBP1-dependent ATR kinase activity approximately 3- to
4-fold higher than undamaged DNA. We conducted kinetic
experiments to analyze the reaction in more detail to determine
the initial reaction rates (Fig. 4B). From these experiments, we
determined that the initial rate of the ATR kinase reaction was
5 times faster with N-Aco-AAF-damaged DNA than with un-
damaged DNA. Qualitatively similar but quantitatively less
significant effects were observed with UV-damaged DNA as
well (SI Fig. 9). Once again, we observed increased specificity of
the reaction under higher ionic strength conditions (SI Fig. 10).
Because several reports indicate that the 30-nt gap produced
by excision repair constitutes a strong signal for the ATR-
mediated checkpoint response (25–27), we considered the pos-
sibility that impurities in our ATR, Chk1, or TopBP1 prepara-
tions were at a sufficient level to excise the base damage and
create excision gaps that would constitute a signal for checkpoint
response. To test for this eventuality, we conducted an ‘‘excision
assay’’ (28, 29) with a mixture of the proteins used for checkpoint
response. No excision was observed (SI Fig. 11), suggesting that
the base damage itself is the signal in our in vitro checkpoint
system.
Dependence of DNA-Binding Activity of TopBP1 for ATR Activation.
The results presented so far are consistent with the idea that
TopBP1 recruits ATR to DNA damage sites and in so doing
stimulate its kinase activity. To test this idea, we measured the
DNA-binding activity of TopBP1 for undamaged vs. N-Aco-
AAF-damaged DNA (Fig. 5A). Full-length TopBP1 bound DNA
with relatively high affinity and with 5-fold preference for
damaged DNA (lanes 5 and 6). Interestingly, the 5-fold
TopBP1-dependent stimulation of ATR kinase activity by N-
Aco-AAF-damaged DNA over undamaged DNA (Fig. 4) cor-
Fig. 1. Purification of human ATR–ATRIP and activation of ATR kinase activity by TopBP1. (A) Scheme of ATR–ATRIP purification from HeLa cell-free extracts.
(B) Purification of ATR–ATRIP. Fractions from the Mono S column were separated on a 5/10% discontinuous SDS/polyacrylamide gel and analyzed by Western
blotting using the indicated antibodies (-) (upper four blots) and by silver staining (lower gel). ATM and DNA-dependent PK catalytic subunit (DNAPKcs) were
separated from fractions containing ATR–ATRIP during chromatography on CM Affi-Gel Blue and DEAE columns, respectively. The peak of ATR–ATRIP eluted
at 220 mM KCl (fraction 8) from the Mono S column. NE, nuclear extract; L, load; E, eluate; FT, flow-through; 1–12, fraction numbers; asterisks, ATR and ATRIP.
The line between the 100- and 150-kDa markers is the boundary between the 5% and 10% acrylamide regions of the gel. (C) Activation of purified ATR kinase
activity by TopBP1. Kinase assays were performed with the Mono S column fractions to test for TopBP1-dependent ATR kinase activity. Mono S load (lanes 1 and
2), flow-through (lanes 3 and 4), and eluted fractions (lanes 5–12) were incubated under low ionic strength reaction conditions (45 mM total salt concentration)
with His-Chk1-kd in the presence or the absence of GST-TopBP1-His. An equal volume of each fraction was preincubated for 15 min at 30°C with 5 nM
GST-TopBP1-His. Chk1-kd (20 nM) was then added into the reaction and incubated for 20 min at 30°C. Reactions were analyzed by immunoblotting for
phosphorylated Chk1 (P-Chk1, which is phosphorylated at S345) (Upper) and total Chk1 (Lower).
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relates with the 5-fold higher binding affinity of TopBP1 to
damaged DNA.
To determine whether DNA binding by TopBP1 was required for
the DNA-dependent stimulation of ATR kinase activity, we used a
C-terminal TopBP1 fragment encompassing amino acids 978-1192,
which is known to activate ATR kinase (14) but lacks DNA-binding
activity (30). In fact, the amino acids 978-1192 fragment did not
bind DNA at moderate enzyme concentrations (Fig. 5A, lanes 7 and
8) and bound only weakly and nonspecifically at 10-fold higher
concentrations (lanes 9 and 10). We conducted ATR kinase assays
to compare the ability of the full-length and the 978-1192 fragment
of TopBP1 to stimulate ATR in the presence or absence of DNA.
In low ionic strength ATR kinase reactions, both the full-length and
the 978-1192 fragment of TopBP1 had similar basal ATR-
stimulatory activities (Fig. 5B, lanes 3 and 7); significantly, however,
only in the presence of the full-length TopBP1 was ATR kinase
activity further stimulated 3- to 4-fold by DNA (lanes 4 vs. 8). Next,
we performed ATR kinase assays with the 978-1192 fragment of
TopBP1 at higher ionic strength to compare the stimulatory effect
of undamaged vs. N-Aco-AAF-damaged DNA (Fig. 5C). The
results reveal that damaged DNA, in agreement with data in Fig.
4, stimulates full-length TopBP1-activated ATR kinase 5-fold
more than undamaged DNA (lanes 3 and 4). In contrast, no or only
marginal stimulation by the 978-1192 fragment of TopBP1 is
observed with damaged or undamaged DNA (lanes 6–13), which
supports the model that TopBP1 binding to damaged DNA is
essential for optimal stimulation of the ATR kinase activity
on Chk1.
Discussion
Data from this study suggest that bulky DNA lesions are recognized
by TopBP1, which recruits ATR to the damage site and potentiates
its kinase activity on the checkpoint signal transduction kinase,
Chk1 (Fig. 6). This human in vitro checkpoint system recapitulates
a number of key features of the checkpoint response. However, the
system in its present form has certain limitations. First, there are
extensive data that primer/template structures, in which the single-
stranded region is covered by RPA, generated by replication blocks
or by nucleotide excision repair are strong signals for checkpoint
activation (22). However, those data and our in vitro findings in this
paper and in vivo data published previously (24) are not necessarily
mutually exclusive because it is quite likely that more than one type
of DNA/protein structure may constitute a signal for checkpoint
activation. Second, in vivo data indicate that in addition to TopBP1,
several other proteins, such as Rad17-RFC, the 9-1-1 complex,
Claspin, and Timeless are required for phosphorylation of Chk1 by
ATR (3, 22). Indeed, a recent study indicates that the Rad9 subunit
of the 9-1-1 complex plays a role in recruitment of TopBP1 to
chromatin and thus facilitates ATR activation by this mechanism
(31). Clearly, establishing an in vitro checkpoint response dependent
on all known checkpoint components, including damaged DNA and
checkpoint proteins, is undoubtedly a challenging problem. How-
ever, we believe that the in vitro system we describe here constitutes
an important framework for incorporation of the other known
checkpoint proteins, which may be required for amplification of the
checkpoint signal observed under our reaction conditions or may be
essential for checkpoint signaling under different and perhaps more
stringent reaction conditions, resulting in reconstitution of a bona
fide human DNA damage checkpoint-signaling pathway in an
entirely defined in vitro system.
Materials and Methods
Antibodies and Checkpoint Proteins. The Chk1 P345 antibody was
purchased from Cell Signaling Technology (Beverly, MA).
ATRIP, ATM, and DNA-dependent PK antibodies were pur-
chased from Novus Biologicals (Littleton, CO). Chk1 and ATR
(N-19) antibodies were purchased from Santa Cruz Biotech-
nology (Santa Cruz, CA). The DNA-dependent PK catalytic
subunit (Ab-4) antibody was purchased from NeoMarkers
(Fremont, CA). GST-TopBP1-His and the GST-TopBP1-
Fig. 2. TopBP1-dependent stimulation of ATR kinase activity by DNA and
effects of ionic strength on this stimulation. (Upper) Kinase assays were carried
out with ATR–ATRIP, His-Chk1-kd, GST-TopBP1-His, and double-stranded DNA
under different ionic strength reaction conditions. ATR–ATRIP (1 nM) was prein-
cubated with or without 5 nM pUC19 plasmid in the presence and absence of 1
nM GST-TopBP1-His. Chk1-kd (20 nM) was then added to the reaction and
incubated for 20 min at 30°C. (Lower) Levels of Chk1 phosphorylation were
quantified, and the results from three independent experiments were averaged
and graphed. Phosphorylation was normalized to the control reaction in lane 1
(without TopBP1 and DNA).
Fig. 3. Stimulation of ATR kinase activity by various DNA substrates in the
presence of TopBP1. (Upper) Kinase assays were performed with ATR–ATRIP,
His-Chk1-kd, GST-TopBP1-His, and different forms of DNA substrates under
high ionic strength reaction conditions (85 mM total salt concentration) as
described in Materials and Methods. ATR–ATRIP (1 nM) was incubated with
1.25–5 nM single-stranded, deca-primed, or double-stranded pIBI25 plasmid
in the presence and absence of 1 nM GST-TopBP1-His. (Lower) The average
levels of Chk1 phosphorylation from three independent experiments were
quantitated and graphed.








(978–11920 fragment were induced in Escherichia coli BL21
RIPL (Stratagene, La Jolla, CA) at 16°C for 5 h. GST-
TopBP1-His was purified with glutathione-Sepharose (GE
Healthcare, Piscataway, NJ), and nickel nitrilotriacetate-
agarose (Qiagen, Valencia, CA), and GST-TopBP1-(978–
1192) fragment was purified with glutathione-Sepharose by
standard procedures. His-Chk1 kinase-dead (Chk1-kd) was
produced by baculovirus infection of Sf21 insect cells (Invitro-
gen) and purified with nickel nitrilotriacetate-agarose beads as
described (16). The p11-tRPA plasmid was obtained from
Fig. 4. TopBP1-dependent stimulation of ATR kinase activity by N-Aco-AAF-damaged DNA. (A) (Upper) Kinase assays were performed with 85 mM final salt
concentration as described in the legend of Fig. 3, except with 0.62–5 nM unmodified (UM) or N-Aco-AAF-damaged (AAF) pUC19 plasmid DNA. (Lower) The
average levels of Chk1 phosphorylation from four independent experiments are quantitated in the graph. (B) (Upper) Time course of Chk1 phosphorylation.
Kinase assays as in A were carried out with 0.62 nM DNA for the times indicated. (Lower) The average levels of Chk1 phosphorylation from two independent
experiments are quantitated in the graph.
Fig. 5. Dependence of DNA-binding activity of TopBP1 for ATR activation. (A) Preferential binding of TopBP1 to N-Aco-AAF-damaged DNA. (Upper) The
indicated amounts of GST-TopBP1-His or the GST-TopBP1-(978–1192) fragment on glutathione-Sepharose beads was incubated at 37°C for 10 min with 1 ng of
unmodified or N-Aco-AAF-damaged DNA that had been 5-end-labeled. Bound DNA was eluted and analyzed by agarose gel electrophoresis. Fifty percent of
the DNA added into the reaction was loaded in the input lanes. (Lower) Data from three independent experiments are presented as means  SD in the graph.
(B) Contribution of DNA-binding activity of TopBP1 to stimulation of ATR kinase activity by double-stranded DNA. (Upper) Kinase assays were performed as in
Fig. 2, except with the TopBP1-(978–1192) fragment compared with full-length TopBP1 under low ionic strength reaction conditions (35 mM total salt
concentration). The TopBP1-(978–1192) fragment (15 nM) was used to obtain a level of Chk1 phosphorylation comparable to that observed with 1 nM full-length
TopBP1 (compare lanes 3 and 7). (Lower) The average levels of Chk1 phosphorylation from two independent experiments are quantitated in the graph. (C)
Requirement of DNA-binding activity of TopBP1 for stimulation of ATR kinase activity by N-Aco-AAF-damaged DNA. (Upper) Kinase assays were performed with
85 mM final salt concentration as in Fig. 4A, except with the TopBP1-(978–1192) fragment (15 nM) compared with full-length TopBP1 (1 nM). For the reactions
containing full-length TopBP1, 5 nM unmodified or N-Aco-AAF-damaged DNA was added. (Lower) The average levels of Chk1 phosphorylation from two
independent experiments are quantitated in the graph.
13304  www.pnas.orgcgidoi10.1073pnas.0706013104 Choi et al.
M. S. Wold (University of Iowa, Iowa City, IA), and RPA was
purified as described (32).
Purification of ATR–ATRIP from HeLa Cell-Free Extracts. Native ATR–
ATRIP complex was isolated from 70 liters of HeLa cells. HeLa
cell-free extracts [80 ml (8.3 mg/ml)] were prepared as described
(33) and applied onto a DE52 column (Whatman, Clifton, NJ).
The flow-through was then loaded onto a CM Affi-Gel Blue
(Bio-Rad, Hercules, CA) column and eluted with 1 M NaCl, and
fractions were collected and analyzed by Western blotting
and silver-staining. The ATR-containing fractions were pooled
and dialyzed against buffer D (20 mM Hepes, pH 7.9/20%
glycerol/0.2 mM EDTA/0.5 mM DTT) containing 100 mM KCl.
It should be noted that this column separates RPA from
ATR–ATRIP quantitatively (34), and as a consequence our
highly purified ATR–ATRIP was free of RPA. The dialyzed
fractions were applied onto a 50-ml DEAE-Sepharose column
(GE Healthcare), and the flow-through was collected and loaded
onto a 20-ml Mono Q column (GE Healthcare) and then eluted
with a 0.1–0.5 M KCl gradient. The ATR-containing fractions
were pooled and dialyzed against buffer D containing 25 mM
KCl. The dialyzed fractions were then loaded onto a 1-ml Mono
S column (GE Healthcare) and eluted with a 25–400 mM KCl
gradient. The peak of ATR–ATRIP complex eluted at 220 mM
KCl. This fraction (0.4 ml, 44 g) was free of DNA-dependent
PK catalytic subunit, and ATM, as determined by Western
blotting, contained 4 g of ATR–ATRIP and was stored
frozen in buffer D containing 220 mM KCl.
Preparation of DNA Substrates for Kinase Assays. Single-stranded or
double-stranded pIBI25 plasmid was purified by standard pro-
cedures. For preparation of deca-primed DNA, ten 30-mers were
hybridized to single-stranded pIBI25 DNA at regular intervals.
The annealing reaction (100 l) contained 10 mM Hepes (pH
7.9), 100 mM NaCl, 9 pmol of each oligomer, and 5 pmol of
single-stranded pIBI25 DNA. The reaction was incubated at
90°C for 3 min and cooled gradually. For N-Aco-AAF-damaged
DNA, pUC19 plasmid was treated with N-Aco-AAF (National
Cancer Institute Chemical Carcinogen Reference Standard Re-
pository, Midwest Research Institute, Kansas City, MO) as
described previously (35) to introduce 20–30 adducts per
plasmid. Briefly, pUC19 (50 g/ml) was treated with 0.3 mM
N-Aco-AAF in 2 mM sodium citrate, pH 7.0, at room temper-
ature for 3 h. The reaction was followed by ether extraction
and ethanol precipitation to remove the nonreacted excess
N-Aco-AAF. For UV irradiation, pUC19 plasmid was irradiated
with 3,000 J/m2 UVC from a 254-nm germicidal lamp, as
determined with a UVX radiometer. After N-Aco-AAF treat-
ment or UV irradiation, the DNA was analyzed on a 0.8%
agarose gel to determine that no additional nicking was intro-
duced by the treatment.
Kinase Assays. Kinase assay reaction mixtures contained 1 M
microcystin, 15 mM Hepes (pH 7.9), 35 mM KCl, 50 mM NaCl,
3 mM MgCl2, 1 mM ATP, 5 mM creatine phosphate, 8 g/ml
creatine kinase, 0.5 mM DTT, 1% polyethylene glycol, and 5%
glycerol in a 10-l final volume. Where indicated, the kinase
assays were carried out with different salt concentrations. Pu-
rified ATR (1 nM) was preincubated for 15 min at 30°C with 1
nM GST-TopBP1-His and 0.62–5 nM DNA. After the preincu-
bation, 20 nM Chk1-kd was added to the reaction, the mixture
was incubated for 20 min at 30°C, unless otherwise indicated, the
reaction was terminated by the addition of SDS/PAGE loading
buffer, and the products were separated by SDS/PAGE. Chk1
phosphorylation was detected by immunoblotting using Chk1
phospho-S345 antibody. For kinase assays with RPA, 5 nM DNA
was first incubated with 0.24–1.92 M RPA for 10 min on ice.
The reaction was then followed by the procedures described
above. For quantification purposes, levels of Chk1 phosphory-
lation were quantified by using ImageQuant 5.2 software (GE
Healthcare) after scanning. The level of Chk1 phosphorylation
in the control reaction (without TopBP1 and DNA) was quan-
titated and set equal to 1. The levels of Chk1 phosphorylation in
the other lanes were determined relative to this value.
DNA-Binding Assays. The procedure was a modification of a
previously described method (30). pUC19 plasmid was linearized
with BamHI and 5-end-labeled with [-32P]ATP by T4 polynu-
cleotide kinase. The labeled DNA was then mock-treated or
treated with N-Aco-AAF as described above. Purified proteins
(3–30 pmol) on glutathione beads were incubated at 37°C for 10
min with the DNA (1 ng) in buffer B [10 mM TrisCl (pH7.7)/1
mM EDTA/0.5% Nonidet P-40) containing 200 mM NaCl. After
the incubation, the beads were washed three times with buffer B,
and bound DNA was eluted by incubation with 0.1 g/l
proteinase K at 37°C for 15 min. The DNA was resolved in a 0.8%
agarose gel, visualized by autoradiography, and quantitated by
using a PhosphorImager (Molecular Dynamics, Sunnyvale, CA)
and ImageQuant 5.2 software.
DNA Excision Assays. The internally radiolabeled DNA substrate
was a 148-bp duplex prepared by ligating a N-Aco-AAF-
damaged oligomer with five other partially overlapping oli-
gomers as described previously (29). Human excision repair
proteins were purified from various sources as described (29, 32).
Substrate DNA (7.5 fmol) was incubated at 30°C for 2 h with
purified excision repair proteins [27 nM xeroderma pigmento-
sum (XP)A/9 nM XPC–HR23B/100 nM RPA/300 ng partially
purified TFIIH/4 nM XPF–ERCC1/5 nM XPG] or with purified
checkpoint proteins (1 nM ATR–ATRIP/1 nM GST-TopBP1-
His/20 nM His-Chk1-kd) in 12.5 l of reaction buffer containing
32 mM Hepes (pH 7.9), 64 mM KCl, 6.4 mM MgCl2, 5% glycerol,
4 mM ATP, and 200 g/ml BSA. After the incubation, the DNA
was purified, resolved in a denaturing 10% polyacrylamide gel,
and visualized by autoradiography.
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Fig. 6. Model of TopBP1-dependent stimulation of ATR kinase activity by
damaged DNA. Data from this study suggest that bulky DNA lesions are
recognized by TopBP1, which recruits ATR to the damage site and potentiates
its kinase activity on the checkpoint signal transduction kinase, Chk1.
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